Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more
Market Cap & Net Worth: Cathay Biotech Inc (688065)
Cathay Biotech Inc (SHG:688065) has a market capitalization of $5.56 Billion (CN¥40.82 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #5020 globally and #605 in its home market, demonstrating a 9.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cathay Biotech Inc's stock price CN¥56.59 by its total outstanding shares 721289794 (721.29 Million).
Cathay Biotech Inc Market Cap History: 2020 to 2026
Cathay Biotech Inc's market capitalization history from 2020 to 2026. Data shows change from $5.85 Billion to $5.56 Billion (-11.19% CAGR).
Cathay Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cathay Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.29x
Cathay Biotech Inc's market cap is 1.29 times its annual revenue
8.83x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
7.80x
Cathay Biotech Inc's market cap is 7.80 times its annual earnings
4.17x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $5.85 Billion | $1.50 Billion | $457.67 Million | 3.90x | 12.77x |
| 2021 | $12.76 Billion | $2.36 Billion | $594.72 Million | 5.40x | 21.46x |
| 2022 | $5.98 Billion | $2.44 Billion | $553.27 Million | 2.45x | 10.81x |
| 2023 | $5.38 Billion | $2.11 Billion | $366.52 Million | 2.54x | 14.68x |
| 2024 | $3.81 Billion | $2.96 Billion | $488.96 Million | 1.29x | 7.80x |
Competitor Companies of 688065 by Market Capitalization
Companies near Cathay Biotech Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Cathay Biotech Inc by market ranking:
- Linde PLC (XETRA:LIN): Ranked #84 globally with a market cap of $187.60 Billion USD ( €182.76 Billion EUR).
- BASF SE NA O.N. (OTCQX:BFFAF): Ranked #459 globally with a market cap of $47.09 Billion USD.
- Shin-Etsu Chemical Co. Ltd (PINK:SHECF): Ranked #467 globally with a market cap of $46.17 Billion USD.
- A. Schulman Inc (PINK:SLMNP): Ranked #824 globally with a market cap of $23.93 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Linde PLC | XETRA:LIN | $187.60 Billion | €430.60 |
| #459 | BASF SE NA O.N. | OTCQX:BFFAF | $47.09 Billion | $53.46 |
| #467 | Shin-Etsu Chemical Co. Ltd | PINK:SHECF | $46.17 Billion | $24.66 |
| #824 | A. Schulman Inc | PINK:SLMNP | $23.93 Billion | $901.00 |
Cathay Biotech Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Cathay Biotech Inc's market cap moved from $5.85 Billion to $ 5.56 Billion, with a yearly change of -11.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.56 Billion | +13.63% |
| 2025 | CN¥4.90 Billion | +28.35% |
| 2024 | CN¥3.81 Billion | -29.09% |
| 2023 | CN¥5.38 Billion | -10.04% |
| 2022 | CN¥5.98 Billion | -53.16% |
| 2021 | CN¥12.76 Billion | +118.34% |
| 2020 | CN¥5.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Cathay Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.56 Billion USD |
| MoneyControl | $5.56 Billion USD |
| MarketWatch | $5.56 Billion USD |
| marketcap.company | $5.56 Billion USD |
| Reuters | $5.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.